Compare Aureon Laboratories vs Canary Foundation
Customers evaluate the quality of Aureon Laboratories's products using the following success metrics.
Aureon Laboratories is 23 yrs old and is based in United States.
Aureon Laboratories is a life science company founded in 2002, dedicated to enabling the advancement of predictive and personalized cancer treatment options. Aureon employs a Systems Pathology approach and provides personalized test results by analyzing a patient's existing biopsy sample using molecular diagnostics, sophisticated tissue-based image analysis and advanced mathematics. The resulting information is objective, predictive and personalized and allows the patient and his doctor to make more-informed treatment decisions. Aureon's technology fits smoothly with existing clinical and pathological processes. Aureon examines formalin-fixed, paraffin-embedded (FFPE) specimens that are routinely obtained as tissue biopsies. Many existing methods need to destroy the tissue architecture to extract protein or genetic biomarkers, losing critical biological information in the process. Vitally important, Aureon's approach retains the biological information embedded in the patient's tissue resulting in improved test performance. In addition to our clinical tests, Aureon also collaborates with bio-pharmaceutical partners to apply our platform to drug discovery and clinical development. Although our initial research focus has been on prostate cancer, we have completed pilot projects in other cancer areas and we are interested in working with partners in the areas of non-small cell lung cancer (NSCLC), breast cancer, bladder cancer, and colorectal cancer. Aureon is a founding member of the 21st Century Medicine Coalition, a member of the Personalized Medicine Coalition, and a member of the American Clinical Laboratory Association (ACLA). Aureon was co-founded by leading physician-scientists at Memorial Sloan-Kettering Cancer Center, Yale Cancer Center, and Albert Einstein College of Medicine.
Canary Foundation is 20 yrs old and is based in United States.
Canary Foundation was founded in 2004 by Don Listwin, a successful high-technology executive who lost his mother to misdiagnosed ovarian cancer. Don discovered that although almost $10 billion is spent annually on cancer research in the United States, the vast majority is allocated to developing new cancer treatments and caring for patients. Surprisingly, little funding is available to researchers investigating new ways to detect cancer it at its earliest, curable stages. Don made a commitment to use his time, energy, expertise, enthusiasm, professional network, and his own family foundation's resources to build a non-profit organization that will succeed at the creation of an early warning system for cancer. His ongoing passion is to build the foundation that connects the very best cancer researchers with entrepreneurs and venture capitalists so that their breakthroughs will have chances of saving lives. Don recruited Dr.Lee Hartwell, 2001 Nobel Laureate, to help form the Canary Science Team from the most outstanding, scientifically researchers available from various disciplines. Science team members come from widely different fields and institutions to meet on a regular basis where they share ideas and breakthroughs. Canary has devised a simple process to provide money and tools for team members to accomplish their stated goals at a rapid pace and with directly applicable results. Tools include software to share data, dedicated websites, project management support, quarterly collaboration meetings and project reviews. One of a decisions the Science Team made was to choose ovarian cancer as a prototype for creating an early detection blood test to detect trace amounts of proteins called biomarkers produced by cancer. Ovarian cancer was chosen as it is generally considered asymptomatic until late stage and has relatively low occurrence. Knowledge, techniques, and data gathered from the Ovarian Cancer Program are being leveraged to expand into other types of cancers (Pancreatic, Prostate and Lung). In addition to blood tests, the Science Team is working on advancing imaging techniques and agents for general body scanning technology using PET, Ultrasound and other imaging modalities for pinpointing the exact cancer location in order to eradicate it while it is still small and before it has spread. Canary hopes that by delivering on a effective test for early detection of cancer it will spur a dramatic increase of funds into the early detection field from the National Cancer Institute and the venture capital community so that products based on this research will arrive faster and save millions of lives per year.
Michael Donovan (Senior Vice President)
Why They Buy
Information not available because Aureon Laboratories has not claimed their profile.
Work for Aureon Laboratories? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Aureon Laboratories?
Claim your profile now.
Information not available because Canary Foundation has not claimed their profile.
Work for Canary Foundation? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Canary Foundation?
Claim your profile now.